Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Jeremy S Abramson,Scott R Solomon,Jon E Arnason,Patrick B Johnston,Bertram Glass,Alessandro Crotta,Sandrine Montheard,Alessandro Previtali,Fei Fei Liu,Julia Braverman,Shien Guo,Ling Shi,Manali Kamdar

doi:10.1182/blood-2021-151611

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Jeremy S Abramson, Scott R Solomon + Show 11 more

Open Access

https://doi.org/10.1182/blood-2021-151611

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 8

Affiliation: Massachusetts General Hospital, Northside Hospital, Beth Israel Deaconess Medical Center, Harvard University, Mayo Clinic, Helios Hospital Berlin-Buch, Bristol-Myers Squibb (Switzerland), Bristol-Myers Squibb (United States), University of Colorado Cancer Center

#Equity Holder In Publicly-traded Company #Current Equity Holder + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Full Text